Hormone receptor-positive human epidermal growth factor 2-negative

Clinical trials for Hormone receptor-positive human epidermal growth factor 2-negative explained in plain language.

Never miss a new study

Get alerted when new Hormone receptor-positive human epidermal growth factor 2-negative trials appear

Sign up with your email to follow new studies for Hormone receptor-positive human epidermal growth factor 2-negative, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

Promising breast cancer combo trial halted early – only 6 patients enrolled

Disease control Stopped early

This phase 2 trial tested repotrectinib with or without fulvestrant in people with a rare, hormone-positive, HER2-negative metastatic breast cancer called invasive lobular carcinoma. The goal was to see if the combination could control the disease after standard treatments had st…

Matched conditions: HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE

Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 08:09 UTC

Hormone receptor-positive human epidermal growth factor 2-negative

Get alerted when new Hormone receptor-positive human epidermal growth factor 2-negative trials appear

Promising breast cancer combo trial halted early – only 6 patients enrolled